Company: QTIWW
Filing Date: 2025-02-05
Form Type: 424B3
Source: 0001628280-25-004061
Chunk: 12

Company: QT IMAGING HOLDINGS, INC.
Filing Date: 2025-02-05
Form: 424B3
Chunk 12
---
 of the Amended Distribution Agreement and for a period of three years after, each party shall not, directly or indirectly solicit for employment the employees of the other except to the extent that such solicitation is done through a general advertisement or solicitation that is not specifically targeting the employees of the other.

<div align='center'>6</div>

#### Table of Contents

#### Our Competitive Strengths
We believe that our competitive strengths include the following:

• The world-wide market for medical imaging is large and it has a potential to expand in the areas where the Company has differentiation;

• a non-ionizing, non-contrast dye injection imaging modality;

• an imaging modality with superior performance as compared to traditional mammogram with respect to specificity (false positive), thus less unnecessary emotional trauma for patients, reduced numbers of invasive follow-up procedures and a reduction of costs for both patient and broader society;

• a lower price point than conventional high-energy imaging equipment;

• the Company’s technology can be deployed to low resources environments (LREs) because of its automation, small footprint, no shielding, no contrast-dye injection;

• the Company’s technology is portable and can be used in point-of-care (POC) settings such as LREs;

• the Company’s technology is deployable in outdoor settings such as sports, military, and naval settings;

• the Company’s technology reduces the barriers to testing and follow up-care for women, as there is no need for specialized training and the technology is well-suited for lowering health care costs by being affordable and easily accessed;

• the Company’s technology provides optimized patient experience, as no radiation is involved, with the patient being able to be followed with no limitation to imaging frequency;

• the Company’s technology is well-suited for traditional tertiary care hospitals and additionally for direct to consumer (DTC) and direct to practitioner (DTP) applications, that are outside these institutions;

• the Company’s technology is uniquely proprietary, disruptive and a one-of-a kind product that can address a variety of unmet medical needs in the medical marketplace; and

• the Company’s products have potential strong revenue growth, with capital purchase or subscription-based recurring revenues supporting substantial long-term gross margin.

#### Our Strategies
We believe that our strategies include the following:

• Create disruptive technological innovation (software, artificial intelligence, and smart physics) to improve medical imaging and thus health care quality and access.

• Continue to improve our high quality, high resolution, native 3D, reproducible image quality regardless of operator or breast